Shanghai Lymphoma Clinical Cohort

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

NCT01476787 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

NCT07200375 ·Status: RECRUITING

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

NCT03715296 ·Status: UNKNOWN

Real World Study of Linperlisib for Lymphoma Treatment

NCT05863871 ·Status: NOT_YET_RECRUITING

Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

NCT00921414 ·Status: COMPLETED ·Phase: PHASE3

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

NCT06151080 ·Status: RECRUITING ·Phase: PHASE2

Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

NCT04164368 ·Status: COMPLETED ·Phase: PHASE2

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

NCT06255704 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1

TreAtments and outComes in paTients With prImary CutAneous Lymphoma

NCT05518851 ·Status: RECRUITING

Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

NCT04842318 ·Status: UNKNOWN ·Phase: PHASE4

A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

NCT05907447 ·Status: UNKNOWN

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

NCT04361279 ·Status: COMPLETED ·Phase: PHASE3

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

NCT06170216 ·Status: ACTIVE_NOT_RECRUITING

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

NCT05923879 ·Status: UNKNOWN

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

NCT07240194 ·Status: RECRUITING ·Phase: PHASE2

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

NCT00209209 ·Status: UNKNOWN ·Phase: PHASE3

A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

NCT04923789 ·Status: UNKNOWN

Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

NCT04481815 ·Status: RECRUITING ·Phase: PHASE2

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

NCT00398177 ·Status: RECRUITING

Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma

NCT04934579 ·Status: COMPLETED ·Phase: PHASE2

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

NCT05821192 ·Status: UNKNOWN ·Phase: NA

Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

NCT05896007 ·Status: RECRUITING ·Phase: PHASE2

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

NCT06656234 ·Status: NOT_YET_RECRUITING

Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

NCT00429065 ·Status: UNKNOWN